DLX6 promotes oral cancer cell proliferation and inhibits apoptosis, and the EGFR-CCND1 signaling pathway may be a potential mechanism involved in the regulatory axis (Liang et al., 2022). Here, DLX6 is linked to lip and oral cavity carcinoma.